Tirzepatide is a relatively new drug that has been shown to have
promising effects on glucose control, weight loss, and cardiovascular
risk factors. It is a dual glucose-dependent insulinotropic peptide
(GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This
combination makes it unique as most GLP-1 receptor agonist drugs do
not activate GIP receptors, which can lead to a more complete response
to glucose challenges.
Cardiometabolic Functional Medicine Information
Several recent studies have demonstrated the potential benefits of
tirzepatide in reducing cardiovascular risk factors. One trial in
particular, the SURPASS-4 study, published in The New England Journal
of Medicine in 2021, evaluated the effects of tirzepatide on
cardiovascular outcomes in adults with type 2 diabetes and established
cardiovascular disease, or at high risk for it. The study found that
tirzepatide significantly reduced major adverse cardiovascular events,
including cardiovascular death, nonfatal myocardial infarction, or
nonfatal stroke, by 15% compared to placebo. Additionally, tirzepatide
was associated with significant reductions in body weight, glycated
hemoglobin levels, and blood pressure.
Another study published in Diabetes, Obesity, and Metabolism in 2021
evaluated the effects of tirzepatide on weight loss and glycemic
control in adults with obesity and type 2 diabetes. The study found
that tirzepatide was associated with significant reductions in body
weight, body mass index, waist circumference, and glycated hemoglobin
levels compared to placebo. The study further found that these effects
on body weight were sustained over time, with patients continuing to
experience weight loss at one year.
Tirzepatide is a promising addition to the treatment options for
diabetes, particularly for patients with cardiovascular disease or at
high risk for it. Its unique dual mechanism of action, combined with
its demonstrated effects on weight loss, glycemic control, and blood
pressure, make it a potentially powerful tool for managing both
diabetes and its associated cardiovascular risks.
Dr. Christopher Davis, M.D. triple board-certified integrative concierge cardiologist and founder and C.E.O of Reveal Vitality in Sarasota, Florida believes that both tirzepatide and semaglutide offer effective cardioprotective and weight loss benefits safely for most clients. These drugs combined with personalized diet and exercise plans based on individual genetic and metabolic profiles can help clients look and feel their best and slow the aging process.
References:
1. Bhatt DL, Szarek M, Steg PG, et al. Effect of Tirzepatide vs
Placebo in Patients with Type 2 Diabetes and Increased Cardiovascular
Risk: Results from the SURPASS-4 Randomized Clinical Trial. N Engl J
Med. 2021 Apr 22;384(16):1508-1519. doi: 10.1056/NEJMoa210
